Searched for
BIOTECH DRUGS
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Karnataka explores biotech financing framework, AI-led innovation to support sector growthKarnataka is developing a dedicated support framework for its biotechnology sector, encompassing funding, mentoring, and regulatory guidanc...
- Ahead of Market: 10 things that will decide stock market action on ThursdayIndian equities lost momentum after a positive start, with Nifty closing lower and broader markets declining sharply. Investor caution ahea...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapseThe US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion...
- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionConcord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...
- Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for u...
- AI-Powered drug discovery could transform treatment development for Alzheimer’s, Parkinson’s and other brain disorders.Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimer’s, Parkinson’s,...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
- Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trialsToregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...
- Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Mark Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapyLast October, Novo Nordisk had shut down its cell therapy unit as part of a broader restructuring, discontinuing development of the therap...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- US market today: Biotech firm Odyssey hits nearly $900 million valuation as shares rise in Nasdaq debutOdyssey Therapeutics debuted on Nasdaq with an 11.1% surge, reaching a $899.9 million valuation. The autoimmune disease specialist successf...
- Sun Pharma gets relief in trademark case from High CourtThe Bombay High Court has ruled in favour of Sun Pharmaceutical Industries. The court has restrained United Biotech from using a similar tr...
- Zydus Biologics’ Ahmedabad injectable facility gets 7 observations in USFDA inspectionZydus Lifesciences has made headlines as its Zydus Biologics injectable plant in Ahmedabad underwent a USFDA inspection between April 27 an...
Load More
